<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120011</url>
  </required_header>
  <id_info>
    <org_study_id>BW2021/RO</org_study_id>
    <nct_id>NCT05120011</nct_id>
  </id_info>
  <brief_title>Carnitine Supplementation and Bone Mineral Density</brief_title>
  <official_title>Effect of Carnitine Supplementation and Resistance Training on Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Physical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Physical Education</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the current research project is to explore whether carnitine&#xD;
      supplementation and resistance training may prevent decrements in bone mineral density of&#xD;
      aged women.&#xD;
&#xD;
      A secondary aim of this project is to investigate the effect of supplementation on body&#xD;
      composition and blood markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes postmenopausal women. The subjects participate in resistance training&#xD;
      (twice a week) for each session consisted of 6 exercises: horizontal seated leg press, seated&#xD;
      chest press, leg extension, shoulder press, lat pull-down seated row, seated cable row.&#xD;
&#xD;
      During the 24-weeks training programme participants are supplemented by carnitine with&#xD;
      leucine, or leucine alone (placebo).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">July 7, 2018</completion_date>
  <primary_completion_date type="Actual">July 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density measured by dual-energy X-ray absorptiometry (DXA)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Bone mineral density (BMD) of the femoral neck, lumbar vertebrae L1-L4, and total hip determined by Lunar Prodigy Advance DXA (GE, Healthcare, Madison, Wisconsin, USA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Composition: Body Fat Mass, Fat Free Mass, and Skeletal Muscle Mass using a bioelectrical impedance analyzer (InBody720).</measure>
    <time_frame>24 weeks</time_frame>
    <description>The InBody720 measures impedance of five segments of the body (each arm, each leg, trunk) at frequencies of 1, 5, 50, 250, 500, and 1000 kHz through the 8-polar tactile-electrode. Based on the impedance, body fat mass, fat free mass, and skeletal muscle mass are calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The circulating markers modification</measure>
    <time_frame>24 weeks</time_frame>
    <description>Determination of serum interleukin-6, tumor necrosis factor alpha, C-reactive protein, and plasma trimethylamine N-oxide.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>carnitine + leucine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>leucine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4000 mg L-leucine per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>L-carnitine-L-tartrate</description>
    <arm_group_label>carnitine + leucine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-leucine</intervention_name>
    <description>L-leucine</description>
    <arm_group_label>carnitine + leucine</arm_group_label>
    <arm_group_label>leucine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  postmenopausal&#xD;
&#xD;
          -  lack of restrictions to perform resistance exercises&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  kidney disease&#xD;
&#xD;
          -  neuromuscular disease&#xD;
&#xD;
          -  gastrointestinal disorders (including stomach ulcers and erosions)&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  other severe chronic diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Olek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Physical Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akademia Wychowania Fizycznego</name>
      <address>
        <city>Poznan</city>
        <zip>61-871</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Physical Education</investigator_affiliation>
    <investigator_full_name>Robert Olek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

